Position Papers
| January 2025 | AVMI Reflections on AVMA – 6 months post launch In June 2024, GAVI launched the $1.2B African Vaccine Manufacturing Accelerator (AVMA) at an event in Paris attended by dignitaries, donors and stakeholders from across the continent and the world. Six months post this milestone event, the African Vaccine Manufacturing Initiative (AVMI), the consensus voice for the African Vx industry, has the following reflections and suggestions in relation to the AVMA Read the Full Paper |
| April 2024 | GAVI AVMA CMO Proposal GAVI has made available an amount of USD750m to 1bn for the AVMA over a 10 year period. The purpose of the AVMA is to achieve sustainable African manufacturing that contributes to the strengthening of a global vaccine market and improved vaccine equity. It also aims to improve Africa’s pandemic outbreak capability and pandemic preparedness. The nexus to achieving these objectives is for African manufacturers to achieve sustainable and predictable demand on the one hand and on the other, economies of scale in order to compete with their contemporaries in other geographies. Read the Full Paper |
| November 2023 | African Vaccine Manufacturing Initiative (AVMI): Briefing Note on the Prioritization of Regulatory Enablers to facilitate accelerated and sustainable African vaccine manufacturing. AVMI considers a progressive regulatory environment at national, regional, continental and at World Health Organisation (WHO) level to be critical to the attainment of Africa’s objectives in relation to health security and equity. Furthermore, AVMI believes that developing, producing and supplying vaccines and other countermeasures to internationally recognised standards is vital to ensuring acceptance by all stakeholders of interventions manufactured on the continent. Read the Full Paper |
| October 2023 | African Vaccine Manufacturing Initiative (AVMI) Position Paper on GAVI’s African Vaccine Manufacturing Accelerator (AVMA) This briefing note documents AVMI’s position and recommendations on the AVMA given that African Manufacturers currently have no formal representation at PPC and the Board. While three African vaccine manufacturers are members of the Developing Countries Vaccine Manufacturers Network (DCVMN), the DCVMN has a large constituent base with diverse interests and therefore does not have a mandate to represent the African vaccine manufacturing industry. Given GAVI’s publicly stated strategic aim to support African Vaccine Manufacturing via the AVMA, the intent of this document is to provide a consensus African industry view. In the future, it is hoped that AVMI is granted representation on the various committees of GAVI similar to what has been afforded to both the DCVMN and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), particularly as the majority of vaccines procured by GAVI are destined for the African continent. Read the Full Paper |